Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%. The move reads as company-specific strength rather than a broad risk-on tape, with market breadth on